发布求助
文献互助 智能选刊 最新文献

Therapeutic immunology最新文献

筛选
英文 中文
Specific down-regulation of anti-allergen IgE and IgG antibodies in humans associated with injections of allergen-specific antibody complexes. 与注射过敏原特异性抗体复合物相关的人抗过敏原IgE和IgG抗体的特异性下调。
Therapeutic immunology Pub Date : 1995-02-01
M G Jacquemin, J M Saint-Remy
{"title":"Specific down-regulation of anti-allergen IgE and IgG antibodies in humans associated with injections of allergen-specific antibody complexes.","authors":"M G Jacquemin,&nbsp;J M Saint-Remy","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Several approaches have recently been put forward describing attempts to suppress the IgE immune response towards allergens, which is thought to be the key event in allergic diseases. In a series of clinical trials we have shown that injections of complexes made up from allergen and specific antibodies are an effective treatment for allergic bronchial asthma and atopic dermatitis. In the work presented here we have examined the humoral immunity changes associated with the use of such complexes in a group of 19 adult patients suffering from atopic dermatitis and hypersensitive to Dermatophagoides pteronyssinus (Dp), and in whom a significant clinical improvement was observed. By comparing serum samples taken prior to and after 4 months of therapy, we show that the administration of immune complexes is associated with: (i) a significant and selective reduction of IgG and IgE antibodies specific for Dp allergens; (ii) a down-regulation that affects only the antibodies present in the complexes; (iii) the induction of corresponding anti-idiotypic antibodies. To our knowledge, this is the first demonstration in humans that an anti-allergen antibody response can be down-regulated in a highly selective manner and that this is accompanied by significant clinical improvement. Moreover, the selective reduction of IgG antibodies could be of value in the treatment of some forms of auto-immune diseases.</p>","PeriodicalId":23039,"journal":{"name":"Therapeutic immunology","volume":"2 1","pages":"41-52"},"PeriodicalIF":0.0,"publicationDate":"1995-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18560250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Induction of a CD8+ cytotoxic T lymphocyte response to soluble antigen given together with a novel muramyl dipeptide adjuvant, N-acetyl-D-glucosaminyl-(beta 1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine (GMDP). 诱导CD8+细胞毒性T淋巴细胞对可溶性抗原的反应，同时给予一种新的muramyl二肽佐剂，n -乙酰- d -葡萄糖氨基-(β 1-4)- n -乙酰muramyl- l- alanyl- d -异谷氨酰胺(GMDP)
Therapeutic immunology Pub Date : 1995-02-01
R L Hornung, D L Longo, V L Gowda, L W Kwak
{"title":"Induction of a CD8+ cytotoxic T lymphocyte response to soluble antigen given together with a novel muramyl dipeptide adjuvant, N-acetyl-D-glucosaminyl-(beta 1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine (GMDP).","authors":"R L Hornung,&nbsp;D L Longo,&nbsp;V L Gowda,&nbsp;L W Kwak","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>We have investigated the ability of the novel muramyl dipeptide, GMDP, to act as an adjuvant for the induction of ovalbumin (OVA)-specific, CD8+ cytotoxic T lymphocyte (CTL) responses. C57Bl/6 mice were twice immunized s.c. with 50 micrograms OVA emulsified with a squalane, L121 pluronic containing Tween-80 vehicle either with (STP-GMDP) or without (STP) GMDP. Splenic precursor CD8+ CTL activity against E.G7-OVA, but not against EL-4 parental targets was detected in STP-GMDP immunized mice after 5 days of in vitro re-stimulation with irradiated E.G7-OVA cells, while mice immunized with OVA in STP alone or OVA alone failed to demonstrate CTL activity. OVA emulsified in a microfluidized STP vehicle formulation without GMDP also elicited the E.G7-OVA precursor CTL. The ability of GMDP to induce a class I-restricted, CD8+ CTL response to a soluble protein antigen may have implications for the development of useful vaccines against viral pathogens or tumours against which CTL responses are desirable.</p>","PeriodicalId":23039,"journal":{"name":"Therapeutic immunology","volume":"2 1","pages":"7-14"},"PeriodicalIF":0.0,"publicationDate":"1995-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18558818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines. 同种异体移植排斥反应中单价抗cd3抗体第一剂量效应的保留与促炎细胞因子释放减少有关。
Therapeutic immunology Pub Date : 1994-12-01
I C Abbs, M Clark, H Waldmann, L Chatenoud, C G Koffman, S H Sacks
{"title":"Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines.","authors":"I C Abbs,&nbsp;M Clark,&nbsp;H Waldmann,&nbsp;L Chatenoud,&nbsp;C G Koffman,&nbsp;S H Sacks","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The murine monoclonal antibody OKT3 is the best known of the anti-CD3 antibodies used for the prevention and treatment of renal allograft rejection. Use of this antibody is associated with improved graft outcome but it has a number of adverse effects thought to result from the massive release of pro-inflammatory cytokines. It has been postulated that OKT3 causes cytokine release because of cross-linking of CD3 molecules on the cell surface by bivalent anti-CD3 antibodies, such as OKT3, and the simultaneous binding of the Fc regions of these monoclonal antibodies to Fc receptors on other cells resulting in cell activation. Monovalent antibodies directed against the CD3 antigen should not, in theory, cause cell activation and cytokine release by this postulated mechanism. This study details the use of a monovalent anti-CD3 monoclonal antibody in the treatment of allograft rejection in five renal transplant recipients and documents the degree of TNF, IFN-g and IL6 release generated after antibody injection. Monovalent anti-CD3 monoclonal antibody reversed the rejection episode for which it was used and was well tolerated in all patients. TNF, IFN-g and IL6 measurement showed that little pro-inflammatory cytokine release occurred after this drug. It is likely that the relative lack of side-effects of monovalent anti-CD3 reflects the blunted release of pro-inflammatory cytokines. Monovalent anti-CD3 monoclonal antibody may be a useful addition to the reagents available to treat allograft rejection.</p>","PeriodicalId":23039,"journal":{"name":"Therapeutic immunology","volume":"1 6","pages":"325-31"},"PeriodicalIF":0.0,"publicationDate":"1994-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18590110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Induced regression of bovine papillomas by intralesional immunotherapy. 瘤内免疫治疗诱导牛乳头瘤消退。
Therapeutic immunology Pub Date : 1994-12-01
H Hall, C Teuscher, P Urie, B Boden, R Robison
{"title":"Induced regression of bovine papillomas by intralesional immunotherapy.","authors":"H Hall,&nbsp;C Teuscher,&nbsp;P Urie,&nbsp;B Boden,&nbsp;R Robison","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>It has long been assumed that papilloma regression is mediated by immunological mechanisms which are probably cellular in nature. The potentiation of these responses may alter the course of papilloma progression. Certain strains of the bacterium Corynebacterium parvum (Propionibacterium acnes) have been shown to augment cellular immune mechanisms by increasing both macrophage and natural killer cell activity. This study involves the use of naturally occurring bovine papillomas to investigate the immune mechanisms involved in induced papilloma regression. Papillomas were treated by intralesional injection of a C. parvum suspension. Treated papillomas were biopsied at various stages of regression. Tissue samples were subjected to immunohistochemical staining to identify specific infiltrating cells. Results showed that intralesional administration of C. parvum was capable of inducing regression of bovine papillomas in 8-15 weeks. Immunological staining revealed that regression was associated with an increased number of CD8+ and gamma delta+ cells in the dermis, as well as a marked infiltration of neutrophils.</p>","PeriodicalId":23039,"journal":{"name":"Therapeutic immunology","volume":"1 6","pages":"319-24"},"PeriodicalIF":0.0,"publicationDate":"1994-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18588935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Better dead than red. 死总比红强。
Therapeutic immunology Pub Date : 1994-12-01
I G Evan
{"title":"Better dead than red.","authors":"I G Evan","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":23039,"journal":{"name":"Therapeutic immunology","volume":"1 6","pages":"343-8"},"PeriodicalIF":0.0,"publicationDate":"1994-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18590112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Differential permeability of the blood-tumour barrier in intracerebral tumour-bearing rats: antidrug antibody to achieve systemic drug rescue. 脑内荷瘤大鼠血肿瘤屏障的差异通透性:抗药抗体实现全身药物救援。
Therapeutic immunology Pub Date : 1994-12-01
R A Kroll, M A Pagel, J J Langone, G J Sexton, E A Neuwelt
{"title":"Differential permeability of the blood-tumour barrier in intracerebral tumour-bearing rats: antidrug antibody to achieve systemic drug rescue.","authors":"R A Kroll,&nbsp;M A Pagel,&nbsp;J J Langone,&nbsp;G J Sexton,&nbsp;E A Neuwelt","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The feasibility of utilizing the differential permeability of the blood-tumour barrier to low- vs. high-molecular-weight compounds is demonstrated in a brain tumour model. Nude rats (n = 27) with or without intracerebral tumours received intravenous [3H]methotrexate (M(r) 454), followed 60 min later by antimethotrexate antibody (M(r) 150,000) or nonspecific mouse antibody. Antimethotrexate antibody resulted in 93% binding of serum methotrexate. In contrast, the percentage of antibody-bound methotrexate in brain and intracerebral tumour was only slightly greater than preantibody protein binding. Methotrexate delivery to tumour was significantly greater than to brain adjacent to tumour and normal brain. The percentage delivery of [3H]methotrexate to all areas of brain was similar between animals receiving antimethotrexate antibody and nonspecific antibody. These findings support the theory that a drug rescue method may be developed that may permit the safe administration of increased dosages of chemotherapeutic drugs for the treatment of intracerebral tumours.</p>","PeriodicalId":23039,"journal":{"name":"Therapeutic immunology","volume":"1 6","pages":"333-41"},"PeriodicalIF":0.0,"publicationDate":"1994-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18590111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Helplessness as a strategy for avoiding antiglobulin responses to therapeutic monoclonal antibodies. 无助作为一种策略来避免对治疗性单克隆抗体的抗球蛋白反应。
Therapeutic immunology Pub Date : 1994-12-01
J D Isaacs, H Waldmann
{"title":"Helplessness as a strategy for avoiding antiglobulin responses to therapeutic monoclonal antibodies.","authors":"J D Isaacs,&nbsp;H Waldmann","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The antiglobulin (anti-Ig) response to therapeutic monoclonal antibodies (mAbs) poses a significant obstacle to their routine application in man. Whilst humanization has lessened the problem, repeated courses of humanized mAbs still sensitise some patients. Previous work suggested that unresponsiveness to cell-binding (therapeutic) mAbs could not be achieved due to an unexpected immunogenicity of their idiotypes (ids). The current work examines this phenomenon in more detail using CBA/Ca mice receiving rat antimouse CD8 mAbs as a model system. It is shown that the anti-Ig response is dependent on CD4+ T-cells. Furthermore, for at least some mAbs, most helper epitopes appear to reside within the mAb c-region. Consequently, when tolerance is induced to c-region (isotype), the anti-id response is extremely weak (induced helplessness). For one (weakly immunogenic) CD8 mAb concomitant administration of a CD4 mAb was sufficient to induce tolerance, whereas for another (more immunogenic) CD8 mAb, tolerance could only be achieved by prior concomitant exposure to both a CD4 mAb and an isotype-matched non-cell-binding mAb. The general applicability of these results is discussed and extrapolated to the clinical situation. Non-cell-binding variants of therapeutic mAbs could be usefully exploited to generate therapeutic unresponsiveness to any clinically useful mAb.</p>","PeriodicalId":23039,"journal":{"name":"Therapeutic immunology","volume":"1 6","pages":"303-12"},"PeriodicalIF":0.0,"publicationDate":"1994-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18588933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Suppressive effect of cyclophosphamide on the progression of lethal graft-versus-host disease in mice--a therapeutic model of fatal post-transfusion GVHD. 环磷酰胺对小鼠致死性移植物抗宿主病进展的抑制作用——致死性输血后GVHD的治疗模型
Therapeutic immunology Pub Date : 1994-12-01
S Uchida, K Suzuki, S Akiyama, M Miyamoto, T Juji, M Fujiwara
{"title":"Suppressive effect of cyclophosphamide on the progression of lethal graft-versus-host disease in mice--a therapeutic model of fatal post-transfusion GVHD.","authors":"S Uchida,&nbsp;K Suzuki,&nbsp;S Akiyama,&nbsp;M Miyamoto,&nbsp;T Juji,&nbsp;M Fujiwara","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In this paper, we examine in a murine system whether cyclophosphamide (CY) could prevent the development of fatal GVHD and furthermore whether it could be used to treat on-going GVHD. (C57BL/6xDBA/2)F1 (BDF1) mice were injected with spleen cells from B6 donors and their thoraces were opened to mimic cardiac operation. These mice lost body weight gradually and most of them died during 2-4 weeks post-transfusion. They showed splenomegaly, thymic atrophy and marked bone-marrow aplasia. When CY was administered at 100 mg kg-1 on days 0, 2, 7 and 9, all mice were relieved of GVHD and their organs were almost free of signs of GVHD. CY (100 mg kg-1) administered on days 7 and 9 also save mice from lethal GVHD. Moreover, CY administered at a dose of 20 mg kg-1 on days 9 and 11 when GVHD became apparent was also effective. These data suggest that CY might be used as a therapeutic agent for lethal post-transfusion GVHD.</p>","PeriodicalId":23039,"journal":{"name":"Therapeutic immunology","volume":"1 6","pages":"313-8"},"PeriodicalIF":0.0,"publicationDate":"1994-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18588934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of cell-mediated immunity in bovine leukemia virus (BLV) infection in ruminants: its implication for the vaccination strategy against retroviruses. 细胞介导免疫在反刍动物牛白血病病毒(BLV)感染中的作用:对逆转录病毒疫苗接种策略的意义
Therapeutic immunology Pub Date : 1994-10-01
M Sugimoto, K Ohishi, Y Ikawa
{"title":"Role of cell-mediated immunity in bovine leukemia virus (BLV) infection in ruminants: its implication for the vaccination strategy against retroviruses.","authors":"M Sugimoto,&nbsp;K Ohishi,&nbsp;Y Ikawa","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Recent studies in the immunopathogenesis of bovine leukemia virus (BLV) infection in ruminants, reviewed herein, provide an insight into the vaccination strategy against retrovirus infection. It was shown that vaccination of naive sheep with a recombinant vaccinia virus (RVV) expressing BLV envelope glycoprotein protected the animals against BLV infection. The involvement of cell-mediated immunity (CMI) in this phenomenon was strongly suggested. The postinfection vaccination, that is, the vaccination of BLV-infected animals with RVV, also significantly suppressed BLV replication in the carrier animals. These findings support the idea that vaccination against retroviruses should put its emphasis on the induction of CMI and that such vaccine could be used not only for prophylactic but also for therapeutic purposes.</p>","PeriodicalId":23039,"journal":{"name":"Therapeutic immunology","volume":"1 5","pages":"297-301"},"PeriodicalIF":0.0,"publicationDate":"1994-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18588932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Considerations in the design and production of small anti-receptor antibody forms: optimizing gains while reducing size. 在设计和生产小抗受体抗体形式的考虑:优化收益，同时减少尺寸。
Therapeutic immunology Pub Date : 1994-10-01
N C Peterson, M I Greene
{"title":"Considerations in the design and production of small anti-receptor antibody forms: optimizing gains while reducing size.","authors":"N C Peterson,&nbsp;M I Greene","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Recent advances which have lead to the cloning of numerous immunoglobulin genes has resulted in the production of a variety of recombinant small antibody-like molecules. These smaller immunoglobulin derived molecules have potential for the development of diagnostic and pharmaceutical compounds. The considerations in the design and production of smaller antibody-like molecules and their clinical applications will be summarized in this review.</p>","PeriodicalId":23039,"journal":{"name":"Therapeutic immunology","volume":"1 5","pages":"289-95"},"PeriodicalIF":0.0,"publicationDate":"1994-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18588931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信